We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on RGNX. REGENXBIO Inc.’s share was trading at $13.76 as of January 15th.
Pressmaster/Shutterstock.com
REGENXBIO is a clinical-stage biotechnology company focused on the development of gene therapies built on its proprietary NAV Technology platform, leveraging AAV8 and AAV9 vectors. Its lead program, surabgene lomparvovec (sura-vec, ABBV-RGX-314),...
